At a glance
ClinicalIndex Comparison RecordN/ACompleted· 295 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
In Brief
An observational study evaluating Ixazomib, Lenalidomide, and 1 other intervention for Relapsed and/or Refractory Multiple Myeloma. Completed, enrolled 295 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the real world effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients with relapsed and/or refractory multiple myeloma (RRMM), under conditions of standard medical care. In addition, an exploratory study of biomarkers will be conducted.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartApr 2018
Primary CompletionJun 2021
TodayJul 2026
First PostedFeb 14, 2018
Enrollment StartApr 2, 2018
Primary CompletionJun 11, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.4 years ago
Interventions
Ixazomibdrug
Ixazomib capsules
Lenalidomidedrug
Lenalidomide capsules
Dexamethasonedrug
Dexamethasone tablets